BOVNF - Transgene and BioInvent on go with study of BT-001 in solid tumors

Transgene (TRGNF) has received approval in France to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001 developed with Invir.IO platform.This announcement follows approval received in December 2020 in Belgium. The first patient is expected to be enrolled in this trial in the upcoming weeks. BT-001 is being co-developed through a 50/50 collaboration between Transgene and BioInvent (BOVNF). In France, four clinical centers will enroll patients. This international study will enroll up to 48 patients with metastatic/advanced solid tumors in its Phase I part followed by expansion cohorts in its Phase IIa part.The trial will evaluate the administration of BT-001 as a single agent and in combination with pembrolizumab, an anti-PD1. The Phase IIa will evaluate the combination regimen in several patient cohorts with different tumors types. These expansion cohorts will offer the possibility of exploring the activity of this approach to treat other malignancies not

For further details see:

Transgene and BioInvent on go with study of BT-001 in solid tumors